Edition:
United States

Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

23.60USD
11 Dec 2017
Change (% chg)

$-1.36 (-5.45%)
Prev Close
$24.96
Open
$25.25
Day's High
$25.50
Day's Low
$23.20
Volume
493,670
Avg. Vol
372,034
52-wk High
$31.80
52-wk Low
$13.13

Chart for

About

Editas Medicine, Inc. is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly... (more)

Overall

Beta: --
Market Cap(Mil.): $994.02
Shares Outstanding(Mil.): 42.12
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 186.11 15.67
EPS (TTM): -- -- --
ROI: -- -11.32 34.62
ROE: -- -35.69 16.00

BRIEF-Editas Medicine Announces Pricing Of $50 Mln Offering Of Common Stock

* EDITAS MEDICINE, INC., ANNOUNCES PRICING OF $50 MILLION OFFERING OF COMMON STOCK

Dec 06 2017

BRIEF-Editas Medicine Announces Offering Of Common Stock

* EDITAS MEDICINE INC - INTENDS TO OFFER AND SELL $50 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING Source text for Eikon: Further company coverage:

Dec 05 2017

BRIEF-Editas Medicine announces Q3 loss per share $0.64

* Editas Medicine announces third quarter 2017 results and update

Nov 07 2017

BRIEF-Editas receives EMA's orphan medicinal product designation for EDIT-101

* Editas Medicine receives EMA's orphan medicinal product designation for EDIT-101 for the treatment of LCA10

Sep 26 2017

BRIEF-Editas Medicine Inc initiates clinical natural history study of Leber Congenital Amaurosis type 10

* Editas Medicine Inc - announced that company initiated a clinical natural history study of Leber Congenital Amaurosis type 10 (LCA10)

Sep 12 2017

BRIEF-Editas Medicine Q2 loss per share $0.65

* Editas Medicine announces second quarter 2017 results and update

Aug 09 2017

BRIEF-Editas Medicine achieves milestone under Juno Therapeutics collaboration

* Editas Medicine achieves milestone under Juno Therapeutics collaboration for technical progress towards overcoming the tumor microenvironment Source text for Eikon: Further company coverage:

Aug 09 2017

Earnings vs. Estimates